Top

American Journal of Clinical Dermatology

Published in:

Open Access 01-04-2018 | Original Research Article

Comparison of Urticaria Activity Score Over 7 Days (UAS7) Values Obtained from Once-Daily and Twice-Daily Versions: Results from the ASSURE-CSU Study

Authors: Kelly Hollis, Christina Proctor, Doreen McBride, Maria-Magdalena Balp, Lori McLeod, Shannon Hunter, Haijun Tian, Sam Khalil, Marcus Maurer

Published in: American Journal of Clinical Dermatology | Issue 2/2018

Abstract

Background

The Urticaria Activity Score summed over 7 days (UAS7) assesses the itch severity and hive count in chronic spontaneous urticaria (CSU) using once- or twice-daily diary-based documentation.

Objective

The aim of this study was to evaluate the comparability of twice-daily versus once-daily versions of the UAS and the resulting UAS7 values.

Methods

Data came from the ASSURE-CSU study. The twice-daily and once-daily UAS7 was calculated from morning and evening ratings, as well as from exact 24-h evening ratings of hive count and itch severity, respectively. Three UAS7 scores were computed: UAS7 twice daily (UAS7_TD), UAS7 once daily for maximum itch (UAS7_OD1MAX), and UAS7 once daily for average itch (UAS7_OD2AVG). UAS7 values were assigned to five score bands (0, 1–6, 7–15, 16–27, 28–42), reflecting urticaria-free to severe disease activity. The score values and score band ratios of the UAS7_TD and UAS7_OD versions were compared and assessed for correlation by weighted Cohen’s kappa statistics.

Results

Data from 614 patients were analyzed. All three versions of the UAS7 yielded very similar results, with a mean (standard deviation) UAS7_TD, UAS7_OD1MAX, and UAS7_OD2AVG of 17.3 (10.49), 17.7 (8.90), and 16.2 (8.68), respectively. Correlation coefficients between UAS7_TD and UAS7_OD1MAX, UAS7_TD and UAS7_OD2AVG, and UAS7_OD1MAX and UAS7_OD2AVG were 0.94, 0.95, and 0.99, respectively, showing very high positive pairwise correlation. The weighted kappa coefficient, κ (95% confidence interval) was 0.78 (0.75–0.82) for UAS7_TD versus UAS7_OD1MAX, and 0.82 (0.78–0.85) for UAS7_TD versus UAS7_OD2AVG, demonstrating substantial agreement.

Conclusions

The once- and twice-daily UAS7 scores were highly consistent, supporting the use of either version when evaluating CSU activity.

Available only for authorised users

Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868–87.CrossRefPubMed

Maurer M, Magerl M, Metz M, Zuberbier T. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Dermatol Ges. 2013;11(10):971–7 (quiz 8).

Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy. 2011;66(3):317–30.CrossRefPubMed

O’donnell B, Lawlor F, Simpson J, Morgan M, Greaves M. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136(2):197–201.

Kang MJ, Kim HS, Kim HO, Park YM. The impact of chronic idiopathic urticaria on quality of life in korean patients. Ann Dermatol. 2009;21(3):226–9.CrossRefPubMedPubMedCentral

EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.CrossRef

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.CrossRefPubMed

Baiardini I, Pasquali M, Braido F, Fumagalli F, Guerra L, Compalati E, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: Chronic Urticaria Quality of Life Questionnaire (CU-QoL). Allergy. 2005;60(8):1073–8.CrossRefPubMed

Snyder CF, Aaronson NK. Use of patient-reported outcomes in clinical practice. Lancet. 2009;374(9687):369–70.CrossRefPubMed

10.

Dobrozsi S, Panepinto J. Patient-reported outcomes in clinical practice. Hematol Am Soc Hematol Educ Program. 2015;2015:501–6.

11.

Mlynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63(6):777–80.CrossRefPubMed

12.

Mathias SD, Dreskin SC, Kaplan A, Saini SS, Spector S, Rosen KE. Development of a daily diary for patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2010;105(2):142–8.CrossRefPubMed

13.

Mathias SD, Crosby RD, Zazzali JL, Maurer M, Saini SS. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2012;108(1):20–4.CrossRefPubMed

14.

US FDA. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. US Department of Health and Human Services. Silver Spring, MD: Office of Communications, Division of Drug information, Center for Drug Evaluation and Research; 2009.

15.

Weller K, Maurer M, Grattan C, Nakonechna A, Abuzakouk M, Berard F, et al. ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria. Clin Transl Allergy. 2015;5:29.CrossRefPubMedPubMedCentral

16.

Maurer M, Abuzakouk M, Berard F, Canonica W, Oude Elberink H, Gimenez-Arnau A, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005–16.

17.

Stull D, McBride D, Tian H, Gimenez Arnau A, Maurer M, Marsland A, et al. Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria. Br J Dermatol. 2017;177(4):1093–1101.

18.

Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRefPubMed

19.

Flood EM, Zazzali JL, Devlen J. Demonstrating measurement equivalence of the electronic and paper formats of the Urticaria Patient Daily Diary in patients with chronic idiopathic urticaria. Patient. 2013;6(3):225–31.CrossRefPubMed

Title: Comparison of Urticaria Activity Score Over 7 Days (UAS7) Values Obtained from Once-Daily and Twice-Daily Versions: Results from the ASSURE-CSU Study
Authors: Kelly Hollis
Christina Proctor
Doreen McBride
Maria-Magdalena Balp
Lori McLeod
Shannon Hunter
Haijun Tian
Sam Khalil
Marcus Maurer
Publication date: 01-04-2018
Publisher: Springer International Publishing
Published in: American Journal of Clinical Dermatology / Issue 2/2018
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-017-0331-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparison of Urticaria Activity Score Over 7 Days (UAS7) Values Obtained from Once-Daily and Twice-Daily Versions: Results from the ASSURE-CSU Study

Abstract

Background

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Teledermatology: A Review and Update

Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual Comparison

Vitamin D and the Skin: An Update for Dermatologists

Topical Corticosteroid Concerns Among Parents of Children with Psoriasis versus Atopic Dermatitis: A French Multicenter Cross-Sectional Study

American Academy of Dermatology Annual Meeting: San Diego, CA, USA, 16–20 Feb 2018

Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond